Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
about
Healthy lifestyles reduce the incidence of chronic diseases and dementia: evidence from the Caerphilly cohort studyProtein phosphatase 2A dysfunction in Alzheimer's diseaseIntracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study.Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 ADMini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populationsInformant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care settingIntravenous immunoglobulin for Alzheimer's diseaseSouvenaid for Alzheimer's diseaseMini-Mental State Examination (MMSE) for the detection of Alzheimer’s dementia and other dementias in asymptomatic and previously clinically unevaluated people aged over 65 years in community and primary care populations11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) settingCSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)IQCODE for the diagnosis of Alzheimer’s disease dementia and other dementias within a general practice (primary care) settingIQCODE for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care settingPassive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's diseaseIQCODE for the diagnosis of Alzheimer’s disease dementia and other dementias within a community setting11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)The accuracy of 18 FDG-PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCIAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will playIntranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidenceMild cognitive impairment: pathology and mechanisms.18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Chocolate, Air Pollution and Children's Neuroprotection: What Cognition Tools should be at Hand to Evaluate Interventions?Ammonia as a Potential Neurotoxic Factor in Alzheimer's DiseaseReview of Sparse Representation-Based Classification Methods on EEG Signal Processing for Epilepsy Detection, Brain-Computer Interface and Cognitive ImpairmentRevolutionizing Alzheimer's disease and clinical trials through biomarkersA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersPathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric DisordersThe Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyCalcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's DiseaseRepurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's diseaseToward precision medicine in Alzheimer's diseaseWhat can imaging tell us about cognitive impairment and dementia?Mouse Genetic Models of Human Brain DisordersAdvances in development of fluorescent probes for detecting amyloid-β aggregatesEarly Dementia ScreeningExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesSuspected non-Alzheimer disease pathophysiology--concept and controversyAlzheimer's disease and language impairments: social intervention and medical treatmentNanotechnology-based drug delivery systems for the treatment of Alzheimer's disease
P2860
Q21089728-988A5F3F-C4AE-4090-A749-956AEDAB5658Q21090465-67B4452D-6618-4518-9754-273F1694ACBDQ22001054-2DBDE082-56FC-4EA2-B39B-02CF9B72E02DQ22252525-15D3336E-098A-4E3F-AA4D-D28A45D3F997Q24186302-40D2DA5B-EE1E-47C5-A5AD-7183A4AB93DDQ24187059-32331BE9-77FB-402C-ADE4-C6E16C870740Q24188215-05B2F96D-858B-4EAD-B421-2EBA2D299AE1Q24188326-50692E34-7127-4AAC-81F2-CF342DA428F5Q24194186-785ADA08-3F52-4CAC-9FF6-387128AB8BCEQ24194742-18451B8A-3047-4141-9695-145C278B3F1DQ24194747-1BCC53C3-7A31-492F-82AA-E86538010D87Q24197654-8F3CF24D-F560-4231-A955-94869B371493Q24197665-6DF04D79-6BC2-4D8E-89E5-A3746CCE9F80Q24197672-CD319BAD-0FFC-4CD0-B5A0-279BFD38472FQ24197852-3B22E8B4-E022-4214-AB0A-53769C6594E3Q24200918-423FA14C-860E-4123-98DC-475A86F52116Q24201039-F166860F-EFE1-4D2F-ABC3-6CEBD10EA780Q24201440-1F3ACF20-7DA3-41DE-ABAA-A9492C8B0454Q24594531-F1B17F2F-95B3-46F6-9B08-BFDE10C2A47CQ24601034-41D28890-CDDB-4055-9D81-A9E420AC172CQ24631255-6EF68FA1-7492-4708-A9C4-FD8531D3480EQ26472008-E758178F-5159-4D79-A6C7-F270CFAC4847Q26738827-DE79670D-6E5A-4D14-8B69-A55AAD1C074BQ26739873-5E088458-D8D9-4149-86F2-27F77BED6C65Q26741601-C001ED0D-B154-4610-AEF5-A4F2945676E2Q26744882-35769EA5-85DA-4CB0-B017-D500178131C9Q26745508-37F15BC4-D3BD-4FA7-8C0F-A2D4C33DB276Q26745690-2AD73874-FAA9-41CF-A59D-89B24D2480EAQ26747107-8BF2168C-56EB-48DB-9B6E-F906944F4754Q26747527-D69892AB-0421-4F0D-978C-42EF7BE2BDBCQ26748711-2F40B972-C85E-4C53-8B2C-012D7913C135Q26748939-55B5E8FB-59DD-4A17-ADE8-29EA729F400AQ26749292-20BB9A56-6779-4776-8F21-7E33CC0B337AQ26752246-C1F2817F-6EE2-433C-8170-75B66C1DC467Q26753175-963B45A8-C17E-4A75-B378-BC2C3AB64DE3Q26770171-BC972148-D856-4102-9F27-EC6823FE35A7Q26770708-72BBDDA4-79A3-4B8C-BB59-395E1BCD4836Q26771270-7FCBEBC8-DB7E-4749-909B-39C4F5CB1A70Q26783205-D98C685C-5730-4739-990F-96FEDB9B72B3Q26783306-FDB9A713-8A09-4872-811B-7B73307F01DF
P2860
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Toward defining the preclinica ...... elines for Alzheimer's disease
@ast
Toward defining the preclinica ...... elines for Alzheimer's disease
@en
Toward defining the preclinica ...... elines for Alzheimer's disease
@nl
type
label
Toward defining the preclinica ...... elines for Alzheimer's disease
@ast
Toward defining the preclinica ...... elines for Alzheimer's disease
@en
Toward defining the preclinica ...... elines for Alzheimer's disease
@nl
altLabel
Toward defining the preclinica ...... elines for Alzheimer's disease
@en
prefLabel
Toward defining the preclinica ...... elines for Alzheimer's disease
@ast
Toward defining the preclinica ...... elines for Alzheimer's disease
@en
Toward defining the preclinica ...... elines for Alzheimer's disease
@nl
P2093
P2860
P50
P3181
P1476
Toward defining the preclinica ...... elines for Alzheimer's disease
@en
P2093
Bill Thies
Christopher C Rowe
Creighton H Phelps
Denise C Park
Eric Siemers
Marcelle Morrison-Bogorad
Molly V Wagster
Reisa A Sperling
Suzanne Craft
Takeshi Iwatsubo
P2860
P304
P3181
P356
10.1016/J.JALZ.2011.03.003
P407
P50
P577
2011-05-01T00:00:00Z